Filing overview
Apimeds Pharmaceuticals US, Inc. filed this Form 8-K regarding executive changes. The report date and earliest reported event are September 29, 2026; the filing was signed September 30, 2026. It does not report periodic financial results.
Financial position and performance
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics.
Management changes
- Interim CFO Erick Frim resigned effective September 29, 2026. The company stated his resignation was not due to a disagreement concerning its operations, policies, or practices.
- The board appointed Eric Sherb as CFO, effective October 1, 2026. He will serve as principal financial officer and principal accounting officer. His fractional CFO engagement at the company’s subsidiary, MindWave Innovations Inc., will terminate in connection with the appointment.
- Sherb’s employment agreement provides for annual base salary of $60,000. The filing says this excludes any potential future equity awards.
Outlook, risks, and unusual items
No financial guidance, business outlook, or specific risks or contingencies are disclosed. The filing describes the executive transitions and compensation arrangement but provides no further financial details.
Investor facts to verify
- Confirm Sherb’s appointment took effect October 1, 2026, and whether any equity compensation is subsequently granted.
- Review subsequent filings for updates on the CFO transition and any material financial or operational disclosures.